MEA Protein Assays Market

MEA Protein Assays Market Size (2024 to 2029)

The Middle East & Africa Protein Assays Market size was calculated at USD 0.16 Billion in 2024. It is further estimated to be growing at a CAGR of 11.31% and worth USD 0.27 Billion by 2029.

Increased investments in pharmaceutical and biotechnology R&D, favorable government laws for proteomics research are a few of the key factors accelerating the growth rate of the MEA protein assays market. In 2022, PhRMA's member organizations (pharmaceutical companies) spent $38.5 billion on research and development, according to a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Various revolutionary biomarker identification technologies and growing new applications for protein assays give players in the MEA protein assay market various opportunities.  Key market participants in the Middle East and Africa protein assay market can benefit from a variety of novel biomarker identification technologies and emerging new uses for protein assays. Minimizing run-times, reducing hands-on time, and employing minimal amounts of patient samples and reagents, the manufacturers implemented new rules to make low-cost proteins available on the market.

High costs associated with the multiplex assay equipment are slightly limiting the growth rate of the Middle East and Africa protein assays market. However, the biggest constraint is infrastructural cost regulation and poor budgeting from government programs. 

This research report on the MEA protein assays market has been segmented and sub-segmented into the following categories.

MEA Protein Assays Market Analysis By Product

• Reagents
• Kits
• Instruments

MEA Protein Assays Market Analysis By Type

• Dye-Binding
• Copper-Ion Based
• Test Strip

MEA Protein Assays Market Analysis By Technology

• Absorbance
• Colorimetric
• Fluorescence

MEA Protein Assays Market Analysis By Application

• Drug Discovery
• Diagnosis

MEA Protein Assays Market Analysis By End User

• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals
• Clinical Laboratories

MEA Protein Assays Market Analysis By Country

• KSA
• UAE
• Israel
• the rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa are projected to record a moderate share in the global protein Assays market during the forecast period. The regional market growth is expected to be driven by the presence of the pharmaceutical and biotechnological industries, a strong trend of R&D in the life sciences industry, and an increase in private partnerships for drug development. In addition, with the increased use of dye-binding assays in illness detection, the Middle East is predicted to grow faster. However, absorbance-based protein tests held a significant market share because of the technology's higher sensitivity and accuracy.

The South African market is predicted to account for the largest share of the MEA protein assays market during the forecast period. Improving healthcare infrastructure, increasing research and development activities, and technological advancements in proteomics are propelling market growth. Regardless, administration organizations, organizations, external managers, and others are concentrating their efforts on developing client-driven products to help the district flourish.

On the other hand, emerging countries such as UAE and Saudi Arabia are estimated to showcase a promising share in the protein assays market during the forecast period. In addition, rising government support in university and institutional proteomics, increasing healthcare expenditure, and availability of advancing healthcare infrastructure are supporting the market growth.

KEY MARKET PLAYERS

A few of the noteworthy companies operating in the Middle East & Africa Proteins Assays Market Profiled in the Report are Abcam PLC., Bio-Rad Laboratories Inc., Biovision Inc., Cell Signaling Technology Inc., GE Healthcare, PerkinElmer Inc., Thermo Fisher Scientific, Geno Technology Inc., Lonza Group, Merck KGaA, Novus Biologicals, LLC.